首页 | 本学科首页   官方微博 | 高级检索  
     


Cetrorelix in an oral contraceptive-pretreated stimulation cycle compared with buserelin in IVF/ICSI patients treated with r-hFSH: a randomized, multicentre, phase IIIb study
Authors:Huirne J A  Hugues J N  Pirard C  Fischl F  Sage J C  Pouly J L  Obruca A  Braat D M  van Loenen A C D  Lambalk C B
Affiliation:1 Division of Reproductive Medicine, Department of Obstetrics and Gynaecology, Vrije Universiteit Medical Centre, Amsterdam, The Netherlands, 2 Hôpital Jean Verdier, Reproductive Medicine Center, University Paris XIII, Paris, France, 3 Universite Catholique de Louvain, Cliniques Universitaires Saint-Luc, Bruxelles, Belgium, 4 Allgemeines Krankenhaus, Universitätsklinik für Frauenheilkunde Abteilung Gynäkologischen Endocrinologie und Reproduktions Medicin Spitalgasse 23, Vienna, Austria, 5 Tour Belledonne, Boulevard Maréchal Leclerc 23, Grenoble, 6 Polyclinique Hotel Dieu, Boulevard Charles-de-Gaulle 13, Clermont-Ferrand, France, 7 Kinderwunschzentrum Wien, Lazarettgasse 16–18, Vienna, Austria and 8 University Hospital Nijmegen, AZ St Radboud, Obstetrecs-Gynaecology, Geert Grootenplein Zuid 1b, GA Nijmegen, The Netherlands
Abstract:BACKGROUND: The aim of this study was to assess the non-inferiorityof an oral contraceptive (OC)-pretreated cetrorelix regimenand a buserelin regimen in IVF/ICSI patients treated with r-hFSHin terms of total number of oocytes retrieved. METHODS: Multicentre,randomized study. One hundred and eighty two patients were randomizedto receive cetrorelix with OC pretreatment (n = 91) or to receivebuserelin (n = 91). The cetrorelix group started with dailyOCs on cycle day 5 and continued for 21–28 days. Cetrorelix(0.25 mg) was given daily from stimulation day 6 up to and includingthe day of r-hCG administration. The buserelin group startedwith buserelin (500 µg/day) for at least 10 days untildown-regulation was achieved, after which the dose was reducedto daily 200 µg up to and including the day of r-hCG administration.r-hFSH was started in both groups on a Friday, in the cetrorelixgroup 5 days after the last OC pill intake. Both regimens werefollowed by a standard IVF or ICSI procedure. The primary efficacyendpoint was the number of oocytes retrieved per patient. RESULTS:Number of oocytes, cancellation rates, r-hFSH requirements,number of oocyte retrievals during the weekend or public holidayand number of pregnancies were similar in both groups. Bothtreatment regimens were well tolerated. CONCLUSIONS: Cetrorelixpretreated with OCs resulted in similar number of oocytes retrievedcompared with a long buserelin protocol. Both regimens werewell tolerated and allowed scheduling of the oocyte retrieval,with only small number of retrievals falling on a weekend orpublic holiday.
Keywords:GnRH agonist/GnRH antagonist/IVF/oral contraceptive/programming
本文献已被 PubMed Oxford 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号